Publication Information

{'id': 'https://openalex.org/W2748547721', 'doi': 'https://doi.org/10.21037/15145', 'title': 'Tumor microenvironments of NSCLC are more heterogeneous than you would think—supported by image analysis-based assessment of PD-L1 and tumor-associated immune cell densities', 'display_name': 'Tumor microenvironments of NSCLC are more heterogeneous than you would think—supported by image analysis-based assessment of PD-L1 and tumor-associated immune cell densities', 'publication_year': 2017, 'publication_date': '2017-08-22', 'ids': {'openalex': 'https://openalex.org/W2748547721', 'doi': 'https://doi.org/10.21037/15145', 'mag': '2748547721'}, 'language': 'en', 'primary_location': {'is_oa': False, 'landing_page_url': 'https://tcr.amegroups.com/article/view/15145', 'pdf_url': None, 'source': {'id': 'https://openalex.org/S2764965054', 'display_name': 'Translational Cancer Research', 'issn_l': '2218-676X', 'issn': ['2218-676X', '2219-6803'], 'is_oa': True, 'is_in_doaj': False, 'is_core': True, 'host_organization': 'https://openalex.org/P4310321814', 'host_organization_name': 'AME Publishing Company', 'host_organization_lineage': ['https://openalex.org/P4310321814'], 'host_organization_lineage_names': ['AME Publishing Company'], 'type': 'journal'}, 'license': None, 'license_id': None, 'version': None, 'is_accepted': False, 'is_published': False}, 'type': 'article', 'type_crossref': 'journal-article', 'indexed_in': [], 'open_access': {'is_oa': False, 'oa_status': 'closed', 'oa_url': None, 'any_repository_has_fulltext': False}, 'authorships': [{'author_position': 'first', 'author': {'id': 'https://openalex.org/A5072389805', 'display_name': 'Mari Mino–Kenudson', 'orcid': 'https://orcid.org/0000-0002-9092-2265'}, 'institutions': [], 'countries': [], 'is_corresponding': True, 'raw_author_name': 'Mari Mino-Kenudson', 'raw_affiliation_strings': [], 'affiliations': []}], 'institution_assertions': [], 'countries_distinct_count': 0, 'institutions_distinct_count': 0, 'corresponding_author_ids': ['https://openalex.org/A5072389805'], 'corresponding_institution_ids': [], 'apc_list': None, 'apc_paid': None, 'fwci': 0.0, 'has_fulltext': False, 'cited_by_count': 0, 'citation_normalized_percentile': {'value': 0.0, 'is_in_top_1_percent': False, 'is_in_top_10_percent': False}, 'cited_by_percentile_year': {'min': 0, 'max': 63}, 'biblio': {'volume': '6', 'issue': None, 'first_page': None, 'last_page': None}, 'is_retracted': False, 'is_paratext': False, 'primary_topic': {'id': 'https://openalex.org/T10158', 'display_name': 'Cancer Immunotherapy and Biomarkers', 'score': 1.0, 'subfield': {'id': 'https://openalex.org/subfields/2730', 'display_name': 'Oncology'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}, 'topics': [{'id': 'https://openalex.org/T10158', 'display_name': 'Cancer Immunotherapy and Biomarkers', 'score': 1.0, 'subfield': {'id': 'https://openalex.org/subfields/2730', 'display_name': 'Oncology'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}, {'id': 'https://openalex.org/T10580', 'display_name': 'Immunotherapy and Immune Responses', 'score': 0.996, 'subfield': {'id': 'https://openalex.org/subfields/2403', 'display_name': 'Immunology'}, 'field': {'id': 'https://openalex.org/fields/24', 'display_name': 'Immunology and Microbiology'}, 'domain': {'id': 'https://openalex.org/domains/1', 'display_name': 'Life Sciences'}}, {'id': 'https://openalex.org/T12505', 'display_name': 'Peptidase Inhibition and Analysis', 'score': 0.9956, 'subfield': {'id': 'https://openalex.org/subfields/2730', 'display_name': 'Oncology'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}], 'keywords': [{'id': 'https://openalex.org/keywords/atezolizumab', 'display_name': 'Atezolizumab', 'score': 0.95776117}, {'id': 'https://openalex.org/keywords/durvalumab', 'display_name': 'Durvalumab', 'score': 0.93519866}, {'id': 'https://openalex.org/keywords/avelumab', 'display_name': 'Avelumab', 'score': 0.9188534}, {'id': 'https://openalex.org/keywords/immune-checkpoint', 'display_name': 'Immune checkpoint', 'score': 0.51004416}], 'concepts': [{'id': 'https://openalex.org/C2780030458', 'wikidata': 'https://www.wikidata.org/wiki/Q7041828', 'display_name': 'Nivolumab', 'level': 4, 'score': 0.9637971}, {'id': 'https://openalex.org/C2775949291', 'wikidata': 'https://www.wikidata.org/wiki/Q20707748', 'display_name': 'Atezolizumab', 'level': 5, 'score': 0.95776117}, {'id': 'https://openalex.org/C2777742743', 'wikidata': 'https://www.wikidata.org/wiki/Q19904005', 'display_name': 'Durvalumab', 'level': 5, 'score': 0.93519866}, {'id': 'https://openalex.org/C2777381376', 'wikidata': 'https://www.wikidata.org/wiki/Q21083261', 'display_name': 'Avelumab', 'level': 5, 'score': 0.9188534}, {'id': 'https://openalex.org/C2780057760', 'wikidata': 'https://www.wikidata.org/wiki/Q13896859', 'display_name': 'Pembrolizumab', 'level': 4, 'score': 0.8931824}, {'id': 'https://openalex.org/C2778468042', 'wikidata': 'https://www.wikidata.org/wiki/Q273976', 'display_name': 'Blockade', 'level': 3, 'score': 0.72212535}, {'id': 'https://openalex.org/C71924100', 'wikidata': 'https://www.wikidata.org/wiki/Q11190', 'display_name': 'Medicine', 'level': 0, 'score': 0.5413629}, {'id': 'https://openalex.org/C143998085', 'wikidata': 'https://www.wikidata.org/wiki/Q162555', 'display_name': 'Oncology', 'level': 1, 'score': 0.5342374}, {'id': 'https://openalex.org/C2780851360', 'wikidata': 'https://www.wikidata.org/wiki/Q21686041', 'display_name': 'Immune checkpoint', 'level': 4, 'score': 0.51004416}, {'id': 'https://openalex.org/C2776256026', 'wikidata': 'https://www.wikidata.org/wiki/Q47912', 'display_name': 'Lung cancer', 'level': 2, 'score': 0.4831821}, {'id': 'https://openalex.org/C2777701055', 'wikidata': 'https://www.wikidata.org/wiki/Q1427096', 'display_name': 'Immunotherapy', 'level': 3, 'score': 0.4639136}, {'id': 'https://openalex.org/C2781053074', 'wikidata': 'https://www.wikidata.org/wiki/Q21100639', 'display_name': 'PD-L1', 'level': 4, 'score': 0.46127272}, {'id': 'https://openalex.org/C535046627', 'wikidata': 'https://www.wikidata.org/wiki/Q30612', 'display_name': 'Clinical trial', 'level': 2, 'score': 0.44943938}, {'id': 'https://openalex.org/C8891405', 'wikidata': 'https://www.wikidata.org/wiki/Q1059', 'display_name': 'Immune system', 'level': 2, 'score': 0.42609632}, {'id': 'https://openalex.org/C126322002', 'wikidata': 'https://www.wikidata.org/wiki/Q11180', 'display_name': 'Internal medicine', 'level': 1, 'score': 0.42577848}, {'id': 'https://openalex.org/C121608353', 'wikidata': 'https://www.wikidata.org/wiki/Q12078', 'display_name': 'Cancer', 'level': 2, 'score': 0.35977572}, {'id': 'https://openalex.org/C203014093', 'wikidata': 'https://www.wikidata.org/wiki/Q101929', 'display_name': 'Immunology', 'level': 1, 'score': 0.3388525}, {'id': 'https://openalex.org/C502942594', 'wikidata': 'https://www.wikidata.org/wiki/Q3421914', 'display_name': 'Cancer research', 'level': 1, 'score': 0.32720625}, {'id': 'https://openalex.org/C170493617', 'wikidata': 'https://www.wikidata.org/wiki/Q208467', 'display_name': 'Receptor', 'level': 2, 'score': 0.2511533}], 'mesh': [], 'locations_count': 1, 'locations': [{'is_oa': False, 'landing_page_url': 'https://tcr.amegroups.com/article/view/15145', 'pdf_url': None, 'source': {'id': 'https://openalex.org/S2764965054', 'display_name': 'Translational Cancer Research', 'issn_l': '2218-676X', 'issn': ['2218-676X', '2219-6803'], 'is_oa': True, 'is_in_doaj': False, 'is_core': True, 'host_organization': 'https://openalex.org/P4310321814', 'host_organization_name': 'AME Publishing Company', 'host_organization_lineage': ['https://openalex.org/P4310321814'], 'host_organization_lineage_names': ['AME Publishing Company'], 'type': 'journal'}, 'license': None, 'license_id': None, 'version': None, 'is_accepted': False, 'is_published': False}], 'best_oa_location': None, 'sustainable_development_goals': [{'display_name': 'Good health and well-being', 'id': 'https://metadata.un.org/sdg/3', 'score': 0.76}], 'grants': [], 'datasets': [], 'versions': [], 'referenced_works_count': 0, 'referenced_works': [], 'related_works': ['https://openalex.org/W3109420266', 'https://openalex.org/W3027700376', 'https://openalex.org/W2970886433', 'https://openalex.org/W2955540054', 'https://openalex.org/W2923986778', 'https://openalex.org/W2894742494', 'https://openalex.org/W2792286951', 'https://openalex.org/W2766583070', 'https://openalex.org/W2765949442', 'https://openalex.org/W2623964361', 'https://openalex.org/W2615570925', 'https://openalex.org/W2612533863', 'https://openalex.org/W2602828273', 'https://openalex.org/W2574563565', 'https://openalex.org/W2554978154', 'https://openalex.org/W2518718160', 'https://openalex.org/W2504822853', 'https://openalex.org/W2462600864', 'https://openalex.org/W2130541026', 'https://openalex.org/W1438640762'], 'abstract_inverted_index': {'In': [0, 23], 'the': [1, 24, 32, 84, 106], 'recent': [2], 'years,': [3], 'blockade': [4, 68], 'of': [5, 20, 26, 66, 76, 96, 103], 'immune': [6], 'checkpoints': [7], 'to': [8, 94], 'reinstitute': [9], 'host': [10], 'antitumor': [11], 'immunity': [12], 'has': [13], 'been': [14, 54], 'extensively': [15], 'investigated': [16], 'in': [17, 72, 83, 105], 'a': [18], 'variety': [19], 'tumors': [21], '(1).': [22], 'field': [25], 'lung': [27, 79], 'cancer,': [28], 'monoclonal': [29], 'antibodies': [30], 'targeting': [31], 'programmed': [33, 45], 'death': [34], '1': [35, 47], '(PD-1)': [36], '(also': [37, 49], 'known': [38, 50], 'as': [39, 51], 'CD279)': [40], 'receptor': [41], 'and': [42, 69, 109, 121], 'its': [43], 'ligand,': [44], 'death-ligand': [46], '(PD-L1)': [48], 'B7-H1)': [52], 'have': [53, 61, 123], 'most': [55], 'studied.': [56], 'High': [57], 'profile': [58], 'clinical': [59], 'trials': [60, 115], 'shown': [62, 125], 'impressive': [63], 'anti-tumor': [64], 'activity': [65], 'PD-1/PD-L1': [67], 'significant': [70], 'improvements': [71], 'overall': [73], 'survival': [74], '(OS)': [75], 'non-small': [77], 'cell': [78], 'cancer': [80], '(NSCLC)': [81], 'patients': [82], 'first-line': [85], 'and/or': [86, 99], 'second': [87], 'or': [88], 'more': [89], 'line': [90], 'settings': [91], '(2-6),': [92], 'leading': [93], 'approval': [95], 'nivolumab,': [97], 'pembrolizumab': [98], 'atezolizumab': [100], 'for': [101], 'treatment': [102], 'NSCLC': [104], 'US,': [107], 'Europe': [108], 'some': [110], 'other': [111, 118], 'countries': [112], '(7).': [113, 128], 'Clinical': [114], 'with': [116], 'two': [117], 'agents,': [119], 'durvalumab': [120], 'avelumab,': [122], 'also': [124], 'promising': [126], 'results': [127]}, 'cited_by_api_url': 'https://api.openalex.org/works?filter=cites:W2748547721', 'counts_by_year': [], 'updated_date': '2024-12-23T20:58:39.473593', 'created_date': '2017-08-31'}